目的：分析探讨阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法将2009年11月至2013年1月期间在我院治疗的105例慢性乙型肝炎患者随机分为两组，观察组58例口服阿德福韦酯片治疗，对照组47例用常规护肝降酶药治疗。48周后比较两组患者HBV-DNA转阴率、HBeAg/HBeAb血清转换率、ALT复常率以及肝纤维化指标变化情况。结果观察组HBV-DNA转阴率、HBeAg/HBeAb血清转换率及ALT复常率均高于对照组（P<0.05）；观察组患者治疗后的肝纤维化指标下降程度优于对照组（P<0.05）。结论阿德福韦酯在抗乙型肝炎病毒的同时延缓了慢性乙型肝炎患者肝纤维化的发生，对慢性乙型肝炎患者远期预后有着积极的影响意义。%Objective To evaluate the clinical efficacy of adefovir in the treatment of chronic hepatitis B. Methods 105 cases of chronic hepatitis B patients in our hospital from November 2009 to January 2013 period were randomly divided into two groups, the observation group of 58 cases was taken with oral adefovir dipivoxil tablets treatment and the control group was taken with conventional liver reduced enzyme medication. The HBV-DNA negative rate, HBeAg/HBeAb seroconversion, ALT normalization rates, and changes in liver fibrosis after 48 weeks for the two groups were compared. Results The HBV-DNA negative rate, HBeAg/HBeAb seroconversion and ALT normalization ratesin the observation group were higher than the control group (P<0.05). After treatment, the degree of decreasing liver fibrosis in the observation group was better than the control group (P<0.05). Conclusion Adefovir dipivoxil in the time of anti-hepatitis B virus in chronic hepatitis B patients delay the occurrence of liver fibrosis, and it has long-term prognosis positive significance on significance for chronic hepatitis B patients.
展开▼
